Overview
QuidelOrtho Corporation is a leading entity in the healthcare industry, primarily focusing on diagnostics healthcare solutions. Based in the United States, the corporation delivers a comprehensive range of products and technologies that are central to diagnostic testing for infectious diseases, cardiometabolic issues, and toxicology. Among its key projects, QuidelOrtho excels in rapid point-of-care testing kits and robust laboratory equipment, which are pivotal in advancing global health standards. The company, through its innovative pursuits, has positioned itself at the forefront of addressing crucial health challenges, implementing streamlined diagnostics that significantly enhance patient care and clinical outcomes. QuidelOrtho's enduring commitment to innovation and accessibility in diagnostic healthcare continues to drive its strategic operations and market expansion.
Basic Stats
The Factor Analysis chart (below right) shows a view of QuidelOrtho Corporation from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | |
| EV | |
| Shares Out. | 67.70 MM |
| Earnings Date | |
| EPS (TTM) | -6.89 |
| Dividend Yield | |
| Ex-Dividend Date | |
| Borrow Rate | |
| Short Shares Avail. | |
| Short Interest | |
| Short Float | |
| Days to Cover | |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | |
| Volatility (1 yr) | |
| Beta | |
| Sharpe Ratio (1 yr) | |
| Sortino Ratio (1 yr) |
| PE Ratio | |
| Price/Book | |
| Price/TBV | |
| Book/Market | |
| EBIT/EV | |
| EBIT(3yr avg)/EV | |
| ROA | -0.07 |
| ROE | -0.15 |
| ROIC | -0.08 |
| CROIC | 0.01 |
| OCROIC | 0.04 |
| Implied Volatility | |
| Put/Call OI Ratio |
| Growth | 20.29 /100 |
| Profitability | 38.85 /100 |
| Quality Score | 39.84 /100 |
| Value Score | |
| Momentum Score | |
| Stability (Low Vol) Score | |
| Analyst Sentiment | |
| Fund Sentiment | 35.36 /100 |
| Insider Sentiment | |
| Officer Sentiment | |
| Dividend Score | |
| QVM Score | |
| Piotroski F-SCORE | 3.00 /9 |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for QuidelOrtho Corporation is US$54.22. The forecasts range from a low of US$43.56 to a high of US$67.39. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for QuidelOrtho Corporation. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2024-05-09 | RBC Capital | Outperform | Outperform | Maintains |
| 2024-03-04 | UBS | Neutral | Sell | Downgrade |
| 2024-02-14 | RBC Capital | Outperform | Outperform | Maintains |
| 2024-02-14 | Craig-Hallum | Buy | Hold | Downgrade |
| 2024-02-14 | William Blair | Outperform | Market Perform | Downgrade |
| 2024-02-14 | Raymond James | Strong Buy | Outperform | Downgrade |
| 2024-02-14 | JP Morgan | Neutral | Underweight | Downgrade |
| 2023-12-21 | RBC Capital | Outperform | Outperform | Maintains |
| 2023-12-11 | Citigroup | Buy | Neutral | Downgrade |
| 2023-11-02 | Raymond James | Strong Buy | Strong Buy | Maintains |
| 2023-09-19 | RBC Capital | Outperform | Outperform | Reiterate |
| 2023-08-15 | Raymond James | Strong Buy | Strong Buy | Maintains |
| 2023-08-09 | RBC Capital | Outperform | Outperform | Reiterate |
| 2023-08-09 | JP Morgan | Neutral | Neutral | Maintains |
| 2023-05-04 | RBC Capital | Outperform | Maintains | |
| 2023-02-16 | RBC Capital | Outperform | Maintains | |
| 2023-02-16 | Raymond James | Strong Buy | Maintains | |
| 2022-12-12 | Citigroup | Neutral | Buy | Upgrade |
| 2022-12-07 | RBC Capital | Outperform | Initiate | |
| 2022-11-03 | JP Morgan | Neutral | Maintains | |
| 2022-10-14 | UBS | Sell | Neutral | Upgrade |
| 2022-09-19 | Citigroup | Neutral | Initiate | |
| 2022-07-20 | UBS | Sell | Initiate | |
| 2022-05-06 | Raymond James | Strong Buy | Maintains | |
| 2022-02-22 | Raymond James | Outperform | Strong Buy | Upgrade |
| 2021-08-06 | Raymond James | Outperform | Maintains | |
| 2021-06-28 | Raymond James | Outperform | Maintains | |
| 2021-06-17 | Craig-Hallum | Buy | Maintains | |
| 2021-06-04 | JP Morgan | Underweight | Maintains | |
| 2021-05-07 | Raymond James | Outperform | Maintains | |
| 2021-03-11 | Craig-Hallum | Buy | Maintains | |
| 2021-03-11 | Raymond James | Outperform | Maintains | |
| 2021-02-19 | Raymond James | Outperform | Maintains | |
| 2021-01-22 | Raymond James | Market Perform | Outperform | Upgrade |
| 2020-07-08 | Piper Sandler | Overweight | Maintains | |
| 2020-05-12 | JP Morgan | Neutral | Underweight | Downgrade |
| 2020-03-26 | Barclays | Overweight | Equal-Weight | Downgrade |
| 2020-02-13 | Raymond James | Strong Buy | Maintains | |
| 2019-04-15 | Raymond James | Strong Buy | Strong Buy | Maintains |
| 2019-03-18 | Barclays | Overweight | Overweight | Maintains |
| 2018-12-11 | Raymond James | Strong Buy | Strong Buy | Maintains |
| 2018-12-11 | Craig-Hallum | Buy | Hold | Downgrade |
| 2018-12-10 | Barclays | Overweight | Overweight | Maintains |
| 2018-09-10 | Canaccord Genuity | Buy | Buy | Maintains |
| 2018-08-14 | Canaccord Genuity | Buy | Buy | Maintains |
| 2018-08-08 | Barclays | Overweight | Overweight | Maintains |
| 2018-08-06 | Barclays | Overweight | Overweight | Maintains |
| 2018-04-02 | Barclays | Overweight | Overweight | Maintains |
| 2018-03-27 | Craig-Hallum | Buy | Initiate | |
| 2018-03-08 | Raymond James | Outperform | Strong Buy | Upgrade |
| 2018-01-04 | CL King | Neutral | Buy | Upgrade |
| 2017-11-02 | Barclays | Overweight | Maintains | |
| 2017-09-19 | PiperJaffray | Neutral | Overweight | Upgrade |
| 2017-09-19 | Barclays | Overweight | Maintains | |
| 2017-09-19 | Canaccord Genuity | Buy | Maintains | |
| 2017-09-19 | Raymond James | Outperform | Maintains | |
| 2017-07-27 | Raymond James | Outperform | Maintains | |
| 2017-07-27 | Barclays | Overweight | Maintains | |
| 2017-07-18 | William Blair | Market Perform | Outperform | Upgrade |
| 2017-07-18 | Canaccord Genuity | Hold | Buy | Upgrade |
| 2017-02-17 | CL King | Neutral | Initiate | |
| 2016-12-16 | PiperJaffray | Overweight | Neutral | Downgrade |
| 2016-06-13 | Raymond James | Market Perform | Outperform | Upgrade |
| 2016-02-18 | Barclays | Overweight | Maintains | |
| 2016-02-09 | Canaccord Genuity | Buy | Hold | Downgrade |
| 2016-01-08 | William Blair | Outperform | Market Perform | Downgrade |
| 2015-12-14 | Raymond James | Outperform | Market Perform | Downgrade |
| 2015-02-12 | Canaccord Genuity | Buy | Maintains | |
| 2014-11-10 | Canaccord Genuity | Buy | Maintains | |
| 2014-07-23 | Raymond James | Outperform | Maintains | |
| 2014-07-23 | JP Morgan | Neutral | Maintains | |
| 2014-07-10 | Wells Fargo | Market Perform | Initiate | |
| 2014-04-24 | Canaccord Genuity | Buy | Maintains | |
| 2013-12-18 | JMP Securities | Market Perform | Initiate | |
| 2013-03-04 | Wedbush | Neutral | Underperform | Downgrade |
| 2013-01-02 | Raymond James | Market Perform | Outperform | Upgrade |
| 2012-10-04 | Stephens & Co. | Overweight | Equal-Weight | Downgrade |
| 2012-10-03 | PiperJaffray | Overweight | Initiate | |
| 2012-10-02 | Cowen & Co. | Neutral | Initiate | |
| 2012-04-26 | JP Morgan | Neutral | Maintains | |
| 2012-03-26 | Canaccord Genuity | Buy | Maintains | |
| 2024-09-19 | UBS | Sell | Neutral | Upgrade |
| 2025-08-07 | UBS | Neutral | Neutral | Maintains |
| 2025-08-06 | Citigroup | Buy | Buy | Maintains |
| 2024-08-01 | RBC Capital | Outperform | Outperform | Reiterate |
| 2025-02-13 | RBC Capital | Outperform | Outperform | Maintains |
| 2025-02-13 | UBS | Neutral | Neutral | Maintains |
| 2024-08-16 | RBC Capital | Outperform | Outperform | Reiterate |
| 2024-12-10 | Jefferies | Hold | Initiate | |
| 2024-09-05 | Craig-Hallum | Hold | Buy | Upgrade |
| 2024-12-11 | Citigroup | Neutral | Buy | Upgrade |
| 2025-04-21 | JP Morgan | Underweight | Underweight | Maintains |
| 2025-05-08 | Jefferies | Hold | Buy | Upgrade |
| 2025-05-08 | UBS | Neutral | Neutral | Maintains |
